In July, TerrAscend paid roughly $9 million for a single dispensary in Flemington. Three months later, on October 6, a New Jersey cannabis operator's collateral is scheduled to go to an Article 9 foreclosure sale.
Same state. Same license framework. Same customers. Wildly different outcomes.
I have been brokering New Jersey businesses for a long time, and I have watched a lot of industries mature. What is happening in NJ cannabis right now is not a downturn and it is not a boom. It is a split. The gap between what a well-run dispensary sells for and what a struggling one sells for has never been wider — and the thing that decides which side you land on is almost entirely within your control.
What the deal data actually says
- Disclosed operational deals in August 2026 averaged roughly $2.0 million per dispensary door, with the volume-weighted figure closer to $2.55 million.
- The high end hit $2.9 million per door. The low end — a distressed portfolio — came in near $1.1 million per door.
- In New Jersey specifically, a Jersey City dispensary is on the market at $2.8 million on roughly $2.77 million in gross sales and a 48.45% gross margin, with a three-year MBE/impact-zone-certified license.
- Meanwhile, Cannabist exited New Jersey entirely, and Vireo Growth is absorbing its locations across five states.
Read those numbers together and the story is obvious. Buyers are not paying for cannabis. They are paying for margin, clean books, and a license that transfers without drama.
Why New Jersey is still a seller's market for the right seller
Two-thirds of New Jersey's 564 municipalities opted out of cannabis sales. That is not a limitation, that is a moat. Scarcity is the single most underpriced asset on a New Jersey cannabis balance sheet.
The market crossed $1 billion in combined recreational and medical sales in 2025, with 300+ dispensaries open since adult-use launched in April 2022. It is a real market with real cash flow.
Consolidators are actively shopping here. When strategic buyers are in acquisition mode, the well-prepared seller gets a competitive process instead of a single take-it-or-leave-it offer.
The two things separating the $2.9M store from the $1.1M store
Provable margin. Not the margin you believe you have — the margin a buyer's accountant can reconstruct from your POS, your Metrc data and your tax returns without you sitting next to them explaining it.
A clean transfer path. A license in good standing, a municipal approval that survives a change of ownership, an assignable lease, ownership disclosures that match reality, and no open CRC compliance items. Buyers price uncertainty.
What changed in 2026 that owners still are not pricing in
- As of April 20, 2026, a Class 5 retailer can operate up to three locations — one main dispensary plus two satellites. That gives a single-location owner an organic growth path and makes an existing license a platform a buyer can expand from.
- Medical marijuana moved from Schedule I to Schedule III in April 2026. Adult-use is not there yet. Dual-licensed operators should be talking to a cannabis CPA now, because the tax profile a buyer underwrites in 2027 may look very different. Talk to your own tax counsel — this is a market observation, not tax advice.
If you are an operator with clean numbers and a transferable license, this is one of the better windows New Jersey has offered, and it will not stay open forever. Consolidators buy in waves, and the wave is here now.
If your numbers are not clean, you have more leverage than you think — but you need 90 to 180 days of disciplined work before anyone sees your file. Reconcile your POS to Metrc to your returns. Get the lease reviewed. Close out compliance items. Document your SOPs. That work routinely moves the number by six figures on a mid-sized store.
And if you are on the buy side, understand that the best New Jersey cannabis opportunities are rarely advertised. Start a confidential conversation when you are ready.